Business · 15/10/2012
National Institutes of Health to Grant Exclusive License for Anti-CD22 CARs for B Cell Malignancies Treatment
The National Institutes of Health is considering granting an exclusive license to practice inventions related to anti-CD22 chimeric antigen receptors (CARs) for the treatment of B cell malignancies, as outlined in U.S. Patent Applications and patents.